Show simple item record

dc.contributor.authorLubov, Janet E.
dc.contributor.authorJamison, Aisha S.
dc.contributor.authorBaltich Nelson, Becky
dc.contributor.authorAmudzi, Alice A.
dc.contributor.authorHaas, Kelly N.
dc.date2022-08-11T08:08:17.000
dc.date.accessioned2022-08-23T15:49:23Z
dc.date.available2022-08-23T15:49:23Z
dc.date.issued2022-03-31
dc.date.submitted2022-04-01
dc.identifier.citation<p>Lubov JE, Jamison AS, Baltich Nelson B, Amudzi AA, Haas KN and Richmond JM (2022) Medicinal Plant Extracts and Natural Compounds for the Treatment of Cutaneous Lupus Erythematosus: A Systematic Review. <em>Front. Pharmacol.</em> 13:802624. doi: 10.3389/fphar.2022.802624. <a href="https://doi.org/10.3389/fphar.2022.802624" target="_blank" title="view article on publisher's site">View article on publisher's site</a></p>
dc.identifier.doi10.3389/fphar.2022.802624
dc.identifier.urihttp://hdl.handle.net/20.500.14038/28421
dc.description.abstractCutaneous lupus erythematosus (CLE) is a group of autoimmune connective tissue disorders that significantly impact quality of life. Current treatment approaches typically use antimalarial medications, though patients may become recalcitrant. Other treatment options include general immunosuppressants, highlighting the need for more and more targeted treatment options. The purpose of this systematic review was to identify potential compounds that could be repurposed for CLE from natural products since many rheumatologic drugs are derived from natural products, including antimalarials. This study was registered with PROSPERO, the international prospective register of systematic reviews (registration number CRD42021251048). We comprehensively searched Ovid Medline, Cochrane Library, and Scopus databases from inception to April 27th, 2021. These terms included cutaneous lupus erythematosus; general plant, fungus, bacteria terminology; selected plants and plant-derived products; selected antimalarials; and JAK inhibitors. Our search yielded 13,970 studies, of which 1,362 were duplicates. We screened 12,608 abstracts, found 12,043 to be irrelevant, and assessed 565 full-text studies for eligibility. Of these, 506 were excluded, and 59 studies were included in the data extraction. The ROBINS-I risk of bias assessment tool was used to assess studies that met our inclusion criteria. According to our findings, several natural compounds do reduce inflammation in lupus and other autoimmune skin diseases in studies using in vitro methods, mouse models, and clinical observational studies, along with a few randomized clinical trials. Our study has cataloged evidence in support of potential natural compounds and plant extracts that could serve as novel sources of active ingredients for the treatment of CLE. It is imperative that further studies in mice and humans are conducted to validate these findings.
dc.language.isoen_US
dc.rightsCopyright © 2022 Lubov, Jamison, Baltich Nelson, Amudzi, Haas and Richmond. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectcutaneous lupus erythematosus (CLE)
dc.subjectnatural compounds
dc.subjectmedicinal plant extracts
dc.subjecttraditional Chinese medicine
dc.subjectherbal formulas
dc.subjectmedicinal mushroom extracts
dc.subjectanti-inflammatory
dc.subjectskin disease
dc.subjectAlternative and Complementary Medicine
dc.subjectDermatology
dc.subjectMedical Pharmacology
dc.subjectPharmacology
dc.subjectSkin and Connective Tissue Diseases
dc.titleMedicinal Plant Extracts and Natural Compounds for the Treatment of Cutaneous Lupus Erythematosus: A Systematic Review
dc.typeArticle
dc.source.journaltitleFrontiers in Pharmacology
dc.source.volume13
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1102&amp;context=derm_pubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/derm_pubs/97
dc.identifier.contextkey28466947
refterms.dateFOA2022-08-23T15:49:23Z
html.description.abstract<p>Cutaneous lupus erythematosus (CLE) is a group of autoimmune connective tissue disorders that significantly impact quality of life. Current treatment approaches typically use antimalarial medications, though patients may become recalcitrant. Other treatment options include general immunosuppressants, highlighting the need for more and more targeted treatment options. The purpose of this systematic review was to identify potential compounds that could be repurposed for CLE from natural products since many rheumatologic drugs are derived from natural products, including antimalarials<em>.</em> This study was registered with PROSPERO, the international prospective register of systematic reviews (registration number CRD42021251048). We comprehensively searched Ovid Medline, Cochrane Library, and Scopus databases from inception to April 27th, 2021. These terms included cutaneous lupus erythematosus; general plant, fungus, bacteria terminology; selected plants and plant-derived products; selected antimalarials; and JAK inhibitors. Our search yielded 13,970 studies, of which 1,362 were duplicates. We screened 12,608 abstracts, found 12,043 to be irrelevant, and assessed 565 full-text studies for eligibility. Of these, 506 were excluded, and 59 studies were included in the data extraction. The ROBINS-I risk of bias assessment tool was used to assess studies that met our inclusion criteria. According to our findings, several natural compounds do reduce inflammation in lupus and other autoimmune skin diseases in studies using <em>in vitro</em> methods, mouse models, and clinical observational studies, along with a few randomized clinical trials. Our study has cataloged evidence in support of potential natural compounds and plant extracts that could serve as novel sources of active ingredients for the treatment of CLE<em>.</em> It is imperative that further studies in mice and humans are conducted to validate these findings.</p>
dc.identifier.submissionpathderm_pubs/97
dc.contributor.departmentLamar Soutter Library
dc.contributor.departmentDepartment of Dermatology
dc.source.pages802624


Files in this item

Thumbnail
Name:
fphar_13_802624.pdf
Size:
2.636Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright © 2022 Lubov, Jamison, Baltich Nelson, Amudzi, Haas and Richmond. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Except where otherwise noted, this item's license is described as Copyright © 2022 Lubov, Jamison, Baltich Nelson, Amudzi, Haas and Richmond. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.